

# Laboratory observational Ex-Vivo study to investigate the sensitivity and specificity of a smart dressing to detect clinically relevant wound infection

<b>Submission date</b> 24/10/2016	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 09/12/2016	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/08/2021	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Burn wound infections are difficult to diagnose, but may become serious if they are not treated quickly. To diagnose an infection, dressings need to be removed from the wound, which may slow the healing process. A new dressing Smartwound™ may help to diagnose wound infection without needing to remove the dressing. The Smartwound™ dressing changes colour in the presence of the infection-causing bacteria. Laboratory studies show that the dressing does change colour in the presence of bacteria, but before it can be used in patients, it needs to be tested with the bacteria found in human wounds. The new Smartwound™ dressing will not be tested on patients in this study. Samples of burn wound fluid, called exudate, which can be taken from wound swabs and used wound dressings when the patients have their dressings removed will be used. Exudate will be gathered from patients with and without wound infection to see whether the dressing changes colour in the presence of the bacteria that cause a wound infection. Dressing changes and swabs are part of the normal care routine for patients with burns. This study aims to test whether the Smartwound™ technology developed to detect infection in a dressing for burn wounds is effective in identifying infection.

### Who can participate?

Patients with burn wounds who either have a suspected infection requiring a dressing change and patients with a burn injury with no signs of an infected wound.

### What does the study involve?

Old standard dressings are collected from patients along with some samples of the burn wound exudate/biofilm (burn wound fluid) using gauze and two cotton swabs. The samples of exudate are taken from the patients during routine treatment. This may be when they are in theatre or in the treatment area, when the wound is being cleaned. The new Smartwound™ dressing is not being tested on patients. The exudate samples are used to test the Smartwound™ dressing in the laboratory. Some medical information relating to the burn wound is collected. Patients are followed up at 14- 21 days to gain information about antibiotic treatment, dressings, additional

medical help and the healing of the burn wound. This is done either at scheduled clinic appointments as part of normal care, or by telephone.

What are the possible benefits and risks of participating?

There are no direct benefits or risks involved to those participating.

Where is the study run from?

1. Bristol Royal Hospital for Children (UK)
2. Southmead Hospital (UK)
3. Queen Victoria Hospital in East Grinstead (UK)
4. Chelsea and Westminster Hospital (UK)

When is study starting and how long is it expected to run for?

June 2015 to April 2018

Who is funding the study?

Medical Research Council (UK)

Who is the main contact?

Dr Natasha Iles

BSCTUEvident@bsms.ac.uk

## Contact information

### Type(s)

Public

### Contact name

Dr Natasha Iles

### Contact details

Brighton and Sussex Clinical Trials Unit

Room 204 Bevendean House

University of Brighton

Brighton

United Kingdom

BN1 9PH

## Additional identifiers

### Protocol serial number

CH/2016/6025

## Study information

### Scientific Title

Laboratory observational Ex-Vivo study to investigate the sensitivity and specificity of a smart dressing to detect clinically relevant wound infection

### Acronym

## EVIDEnT: Ex Vivo Infection DETection

### Study objectives

The aim of this diagnostic accuracy study is to estimate the sensitivity, specificity, for the infection detection 'smart' technology.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

South West - Cornwall & Plymouth Research Ethics Committee, 02/09/2016, ref: 16/SW/0238

### Study design

Multi-centre prospective ex-vivo diagnostic technology development study

### Primary study design

Observational

### Study type(s)

Other

### Health condition(s) or problem(s) studied

Burn wound infection

### Interventions

The old dressing and exudate soaked gauze will be sent to the laboratory at University of Bath to assess the smart wound technology 'switch-on' i.e. colour change. A standard swab will be sent for routine hospital microbiology analysis (MC+S) and a clinical assessment of wound infection by observation will be performed. A swab will also be sent to the laboratory at University of Brighton for qPCR testing to determine the levels of bacterial toxins present to validate the technology responsiveness and the clinical definition of wound infection. The patient will be followed up by means of a telephone call or face-to-face if they have a routine visit scheduled at 14-21 days for a retrospective confirmation of whether the wound was infected or not.

### Intervention Type

Biological/Vaccine

### Primary outcome(s)

1. Technology switched on or remained off is measured by observing colour change in the laboratory at baseline
2. Clinically relevant wound infection or no infection is assessed using clinical decisions, taking into account observation of wound, laboratory markers of inflammation and infection, wound and blood microscopy and culture and response to antibiotics at baseline. A follow-up review at 14-21 days will be carried out to confirm retrospectively the wound infection assessment at baseline.

### Key secondary outcome(s)

Levels of bacterial toxins to validate both clinical definition of wound infection and technology switch-on is measured using qPCR at baseline.

**Completion date**

24/04/2018

## **Eligibility**

**Key inclusion criteria****Control group**

1. Patients with burns of all types and sizes
2. Any child from 4 weeks up to the age of 16 years/adults up to 100 years
3. >48 hrs after injury but before healing complete
4. Wound dressings intact
5. No signs of wound infection
6. Not currently using antibiotics
7. Consent gained for study

**Suspected infection group**

1. Patients who present with a suspected burn wound infection as determined by the reference standard.
2. A child/adult with burns
3. Any child from 4 weeks up to the age of 16 years/adults up to 100 years
4. Wound dressings intact
5. Not on antibiotics for longer than 24 hours
6. Consent gained for study

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Sex**

All

**Total final enrolment**

344

**Key exclusion criteria****All participants:**

1. Child < four weeks of age/adults above 100 years
2. Consent not gained for study
3. Adult without mental capacity to consent
4. A child/adult who is on antibiotics for longer than 24 hours
5. No wound dressings

**Date of first enrolment**

13/01/2017

**Date of final enrolment**

26/04/2018

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****Bristol Royal Hospital for Children**

Paul O'Gorman Building

Upper Maudlin Street

Bristol

United Kingdom

BS2 8BJ

**Study participating centre****Southmead Hospital**

Dorian Way

Westbury-on-Trym

Bristol

United Kingdom

BS10 5NB

**Study participating centre****Queen Victoria Hospital**

Holtye Road

East Grinstead

United Kingdom

RH19 3DZ

**Study participating centre****Chelsea and Westminster Hospital**

369 Fulham Road

London

United Kingdom

SW10 9NH

**Sponsor information**

**Organisation**

University Hospitals Bristol NHS Foundation Trust

**ROR**

<https://ror.org/04nm1cv11>

## Funder(s)

**Funder type**

Research council

**Funder Name**

Medical Research Council

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository.

**IPD sharing plan summary**

Stored in repository

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Participant information sheet</a>	version V2.2	30/09/2016	09/12/2016	No	Yes
<a href="#">Participant information sheet</a>	version V2.2	30/09/2016	09/12/2016	No	Yes
<a href="#">Participant information sheet</a>	version V2.2	30/09/2016	09/12/2016	No	Yes

<a href="#">Participant information sheet</a>	version V2.2	30/09/2016	09/12/2016	No	Yes
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Preprint results</a>	preprint results	23/07/2021	17/08/2021	No	No